Deslorin Plus

Quick links to important sections

Deslorin Plus

Method of action: Antitussive

Treatment option: Blocked Nose, Rhinitis, Hay Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deslorin Plus

Property Description
Active ingredients Desloratadine, Pseudoephedrine
Form Oral tablet
Pharmacological class Antihistamine and Decongestant Combination
Common use Symptomatic relief of allergic rhinitis
Origin Synthetic

What Type of Medicine is Deslorin Plus?

Deslorin Plus is a synthetic fixed-dose combination medication classified broadly as an Antihistamine and Decongestant Combination. This specific brand is manufactured as an oral tablet for systemic use, ensuring its active components are distributed throughout the body. The drug belongs to the therapeutic class of Upper Respiratory Combinations, a strategy clinically recognized for effectively managing multiple concurrent symptoms such as those encountered during severe allergy seasons.

The Active Components: Desloratadine and Pseudoephedrine

The formulation combines the actions of two distinct active ingredients: Desloratadine and Pseudoephedrine. Desloratadine is identified as a non-sedating, second-generation tricyclic histamine antagonist, which is the component designed to address the underlying allergic reaction. The use of a second-generation compound supports its established pharmacological profile for reduced risk of drowsiness compared to older agents. The second component, Pseudoephedrine, is classified as a powerful sympathomimetic amine and an alpha-adrenergic agonist, serving as the primary decongestant agent.

General Purpose and Benefit of the Dual Action

The general purpose of Deslorin Plus is to provide comprehensive symptomatic relief, often used by adults and adolescents experiencing significant discomfort from seasonal allergic rhinitis accompanied by severe nasal congestion. The dual mechanism is clinically supported for its efficacy: the antihistamine component counteracts the effects of histamine responsible for classic allergy symptoms, while the decongestant component physically reduces nasal airway obstruction, a benefit widely confirmed in clinical practice guidelines. This ensures that the medication addresses both the allergic irritation and the physical difficulty in breathing.

What side effects are possible with Deslorin Plus?

Possible Side Effects and Safety Information

The safety profile for this fixed-dose combination medication is defined by the officially documented adverse reactions and strict regulatory limitations related to the two active components: Desloratadine (antihistamine) and Pseudoephedrine (decongestant).


Common Adverse Reactions

The most frequently documented side effects in regulatory sources are classified primarily under Nervous System Disorders and Gastrointestinal Disorders. Reactions reported as Common (ge 2% in clinical trials) include Insomnia (trouble sleeping), Headache, Dry Mouth, and Fatigue.


Serious Reactions and Organ System Risks

Regulatory documents list the potential for serious adverse reactions, often associated with the decongestant component's effects on the Cardiovascular System and CNS. These include severe Hypersensitivity Reactions such as anaphylaxis and angioedema, Seizures, and the potential for cardiovascular events like Tachycardia or Palpitations.


Safety Restrictions and Special Populations

Due to the profile of Pseudoephedrine, the regulatory label imposes explicit constraints. The medicine is contraindicated in individuals with severe hypertension, severe coronary artery disease, narrow-angle glaucoma, or those concurrently taking Monoamine Oxidase (MAO) inhibitors.

Specific caution and avoidance are also required for certain patient groups:

  • Severe Organ Impairment: The medication is generally not recommended for patients with severe renal or hepatic impairment.
  • Older Adults ( ge 60 years): This population is advised to use the medication with caution, as they may be more susceptible to CNS and cardiovascular effects.
  • Pediatric Use: Use is not recommended in the pediatric population under 12 years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the manifestations and required actions for Deslorin Plus overdose as officially documented in government regulatory labeling (e.g., FDA, EMA).

Overdose symptoms are primarily related to the effects of the decongestant component and may involve a progression from central nervous system (CNS) stimulation to depression.

System Manifestation Documented Signs/Symptoms (Official Labeling)
Central Nervous System (CNS) Stimulation (e.g., tremors, hallucinations, excitement) or Depression (e.g., sedation, coma, apnoea).
Cardiovascular System Tachycardia, cardiac arrhythmias, hypertension, hypotension, and cardiovascular collapse.

Severe Outcomes and Emergency Action

Regulatory documents highlight the potential for severe outcomes, including convulsions, respiratory failure, and cardiovascular collapse, which may result in a fatal outcome. These severe effects are noted as more likely to occur in adolescents and the elderly in the context of overdose.

There is no specific antidote documented for Deslorin Plus overdose. Management is restricted to symptomatic and supportive treatment and considering measures to remove any unabsorbed substance.

When to Seek Urgent Medical Help

  • Seek immediate medical attention or call the poison control helpline for any suspected overdose.
  • Immediately call emergency services if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Therapeutic Uses of Deslorin Plus

Quick Facts: What Deslorin Plus May Help Address

  • Relief of Symptoms: Helps to manage the signs associated with allergic rhinitis, including seasonal and perennial forms.
  • Nasal Comfort: Contributes to the reduction of nasal congestion and stuffiness.
  • Non-Nasal Symptom Management: Assists in the management of non-nasal symptoms related to allergies.

What Deslorin Plus Treats: Main Uses and Benefits

Deslorin Plus is authorized to provide symptom management for individuals experiencing allergic rhinitis. Allergic rhinitis is a common condition involving inflammation of the nasal passages due to an allergy, such as hay fever or dust mite sensitivity. This medicine contains a combination of two agents, an antihistamine and a nasal decongestant, which work together to address specific signs.

The medication is used to mitigate the discomfort linked to both seasonal and perennial allergic conditions. A primary function is to support the reduction of symptoms in the nose, throat, and eyes, which may include sneezing, running of the nose, and itching. Furthermore, the decongestant component assists in improving nasal airflow by helping to alleviate nasal stuffiness and congestion.

It is important to understand that this medication is intended for the relief of symptoms and is not a cure for the underlying allergic condition.

Eligibility and Restrictions for Use

Who Can and Cannot Use Deslorin Plus?

This section outlines the officially documented population eligibility and non-eligibility for Deslorin Plus (Desloratadine/Pseudoephedrine combination), as defined by government regulatory authorities.


Eligibility and Age Rules

Use of this medicine is authorized for Adults and Adolescents aged 12 years and older. The medicine is not recommended for children below 12 years of age, as safety and efficacy have not been established for this age group in the combination product.


Absolute Contraindications (Must Not Use)

Deslorin Plus is contraindicated in patients with known hypersensitivity to any of its components, including desloratadine, pseudoephedrine, or loratadine. Absolute exclusions also apply to individuals who are currently taking or have stopped using a Monoamine Oxidase (MAO) inhibitor within the last 14 days.

Contraindications based on pre-existing conditions include severe or uncontrolled hypertension, ischaemic heart disease, tachyarrhythmia, hyperthyroidism, narrow-angle glaucoma, or urinary retention.


Conditional Restrictions and Physiological Status

Use is not recommended in patients with established renal or hepatic impairment due to insufficient data for dose recommendations. The product should not be used during breastfeeding, and use during pregnancy is preferable to avoid as a precautionary measure. Caution is advised for use by older adults and patients with conditions such as diabetes mellitus, controlled hypertension, or prostatic hypertrophy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Deslorin Plus, a combination of Desloratadine and Pseudoephedrine, is defined by mandated prohibitions and pharmacokinetic modifications documented in regulatory sources.


Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the Pseudoephedrine component’s risk of causing hypertensive crisis. A specific timing rule requires a minimum of 14 days to elapse between discontinuing MAOI therapy and initiating Deslorin Plus. The combination is also generally prohibited with other Sympathomimetic Decongestants and Beta-blockers due to additive cardiovascular risks.


Pharmacokinetic and Pharmacodynamic Interactions

Interactions with Ketoconazole (antifungal) and Erythromycin (antibiotic) are formally documented to cause a clinically significant increase in the plasma concentrations of desloratadine and its metabolite. This is attributed to the inhibition of Desloratadine’s hepatic metabolism.

Pharmacodynamic additive effects occur with Alcohol (Ethanol) and other Central Nervous System (CNS) Depressants, which may worsen the drug’s potential sedative effects. The Pseudoephedrine component also poses a documented risk of potentially provoking ventricular arrhythmias if used concurrently with Halogenated Anaesthetic Agents during surgery.


Population-Specific Notes

The effects of exposure-modifying interactions may be more relevant in patients with documented Renal Impairment or Hepatic Impairment, and the combination product is generally not recommended in cases of severe impairment.

Mechanism of Action

Interrupting the H1 Receptor Signaling Cascade

This mechanistic domain is governed by Desloratadine's action as a selective antagonist of peripheral Histamine Type 1 receptors. By binding to these receptors, the drug prevents the major inflammatory mediator, histamine, from initiating its signaling sequence . This interference with the chemical trigger of inflammation modulates increased vascular permeability and restricts fluid exudation and nerve ending sensitization in the respiratory system.


Modulating Vascular Tone via alpha -Adrenergic Activation

This domain involves Pseudoephedrine's role as a sympathomimetic, acting as an agonist on alpha -adrenergic receptors located primarily in the nasal microvasculature. Activation of these receptors prompts the smooth muscle surrounding the nasal arterioles to contract, leading to localized vasoconstriction . This targeted action regulates regional blood flow and causes a physical change to the blood volume of the engorged tissue within the nasal mucosa.


Complementary Mechanism Dualism

The overall physiological outcome is defined by its mechanistic dualism: the two components independently target the distinct processes of chemical inflammation and physical vascular engorgement. This synergistic approach ensures the modulation of both the histaminergic pathway and the sympathetic pathway simultaneously, resulting in a coordinated modification of the physiological state of the upper respiratory mucosa.

Dosage and Administration Information

How to Use Deslorin Plus: Official Administration Guidelines

The usage of Deslorin Plus, a fixed-dose combination of desloratadine and pseudoephedrine, is defined based on its modified-release formulation. The medicine is authorized for oral use only and is indicated for adults and adolescents 12 years of age and older.


Official Dosing and Frequency

The standard dosing regimen is governed by the specific strength of the modified-release tablet, which dictates the frequency of administration.

Formulation Strength Dosing Frequency Maximum Dose Rule
2.5 mg Desloratadine / 120 mg Pseudoephedrine One tablet twice a day (12-hour interval) Do not exceed one tablet every 12 hours
5 mg Desloratadine / 240 mg Pseudoephedrine One tablet once a day (24-hour interval) Do not exceed one tablet every 24 hours

Administration Requirements and Duration

For the extended-release mechanism to function correctly, the tablet must be swallowed whole and must not be broken, crushed, or chewed. This administration rule prevents the rapid release of the pseudoephedrine component. The tablet can be taken with or without food.

Use of this combination product is generally intended to be short-term, as it is typically advised to limit treatment duration to about 10 days. If a dose is missed, patients should resume the standard schedule by taking the next dose at the usual time.

Recent Clinical Evidence

Research Examining Symptom Management in Seasonal Allergic Rhinitis

Research examining this combination is primarily sourced from controlled, short-term research, consisting of Randomized Controlled Trials (RCTs). This design was used in research exploring short-term symptom changes in conditions characterized by fluctuating or episodic manifestations, such as Seasonal Allergic Rhinitis (SAR). These studies monitored patient experiences under study conditions.

The trials were designed to directly compare the combination formula against a non-active placebo and against the individual components: desloratadine alone and pseudoephedrine alone. This approach defined the study conditions under which the combined use was compared to single-ingredient options. Findings describe patterns observed in the studies related to patient-reported outcomes describing perceived discomfort during periods of increased symptom activity. Research recorded measurements of changes during the study period, particularly in comparison to the initial baseline symptom levels.

Study Designs and Measured Outcomes

The clinical trials were applied in studies examining patient-reported experiences, focusing on individuals who presented with noticeable nasal congestion alongside other typical allergy issues. Research examined outcomes related to observable symptom severity and outcomes describing episodic or acute changes.

The primary data gathered included patient-reported scoring scales for Total Symptom Scores (TSS). These scores were used in research exploring how symptoms change over time, monitoring issues like sneezing, runny nose, and itching. A specific outcome that was studied was the Nasal Congestion Score, which is a type of patient-reported outcome describing perceived discomfort for nasal stuffiness.

Follow-up Durations and Research Gaps

The primary clinical trials that were evaluated in this combination's research profile were observed in settings exploring short-term symptom changes. For the most part, follow-up durations were limited, typically spanning up to 15 days or two weeks.

Due to the limited time frame of these core trials, long-term effects are not fully established. Research so far indicates data on continuous use is insufficient for conclusions about the durability of one component’s effects over extended time periods. Additionally, the research was evaluated in a defined population of adults and adolescents (12 years of age and older); data for certain groups remain insufficient, and evidence remains limited for conditions other than Seasonal Allergic Rhinitis.

Frequently Asked Questions (FAQ)

Common questions about Deslorin Plus (FAQ)


Q: Can Deslorin Plus be taken for symptoms other than allergies, like a cold?

A: Official drug labels indicate that this combination product is used to temporarily relieve nasal congestion caused by the common cold, in addition to symptoms from upper respiratory allergies. The product is approved for use when relief from both an allergy component and nasal stuffiness is desired.

Q: Is it okay to drive or operate machinery after taking Deslorin Plus?

A: Regulatory documents advise that, due to potential side effects like dizziness and somnolence (sleepiness), it is advised that activities requiring mental alertness, such as driving or using heavy machinery, should be avoided until an individual knows how the medicine affects them. Individual responses can vary, and official information focuses on minimizing potential impairment.

Q: What is the recommended period of time for continuous use of Deslorin Plus?

A: Treatment should be kept as short as possible. According to official product information, it is advised to limit the duration of use to about 10 days. The product is not intended for continuous long-term use, and official labels caution against exceeding the recommended dose frequency.

Q: Has Deslorin Plus been studied in people with asthma?

A: Clinical studies have examined the use of the fixed combination product in patients who had seasonal allergic rhinitis and co-occurring mild to moderate asthma. Research suggested that the medicine did not appear to impair pulmonary function in the study conditions. However, the product’s official approved use is specifically for allergic rhinitis.

Q: What happens if you accidentally take more Deslorin Plus than intended?

A: If a greater amount than the recommended dose is taken, official documents advise that it is advised to seek medical help or contact a Poison Control Center right away. Symptoms of an overdose may include a fast or irregular heartbeat, extreme drowsiness, mental or mood changes, and potentially seizures. Symptomatic and supportive care is recommended.

Q: Do regulatory agencies classify Deslorin Plus as a drug with high interaction risk?

A: Regulatory documents list several severe or major interactions that require strict caution. For example, it is contraindicated (must not be used) with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of a hypertensive crisis. Interactions with cardiovascular agents and CNS depressants are also noted, indicating a necessity for careful review.

Q: Can Deslorin Plus be taken with antacids or heartburn medication?

A: Official drug information documents indicate that certain antacids can increase the rate at which the decongestant component, pseudoephedrine, is absorbed into the body. Conversely, other agents like kaolin are documented to decrease its absorption. Regulatory documents describe changes in absorption when taken with antacids, which is a factor considered in the official interaction profile.

Q: Does Deslorin Plus cause weight gain or changes in appetite?

A: Official regulatory documents list a decreased appetite (anorexia) as an uncommon adverse reaction associated with this medication. While weight loss has been noted as a less common side effect, weight gain is generally not documented among the frequently reported adverse reactions.

Q: How long does it typically take for Deslorin Plus to start working?

A: The antihistaminic effects generally begin to occur within 1 hour after the tablet is taken. Clinical trials indicate that patients observed overall symptomatic improvement as early as 1 day after starting the therapy.

Q: What kind of studies support the claims made about Deslorin Plus?

A: The claims are supported primarily by Randomized Controlled Trials (RCTs). These studies demonstrated that the combination tablet produced a significant reduction in patient-reported nasal congestion scores compared with taking the individual components (desloratadine or pseudoephedrine) alone.

Q: Are the side effects of Deslorin Plus different for men and women?

A: Pharmacokinetic studies have been conducted and found no clinically significant differences in the levels of the active ingredients in the blood based on gender. Because of this finding, regulatory documents do not advise any specific dosage adjustments based on whether the patient is male or female.

Q: Are there any known visual side effects from taking Deslorin Plus?

A: Yes, official regulatory documents list 'vision blurred' and 'dry eye' as uncommon side effects. Additionally, the drug is contraindicated in patients with a specific eye condition called narrow-angle glaucoma because of the risk of increased pressure within the eye.

Q: Can people with a known lactose intolerance use Deslorin Plus?

A: The official product information lists lactose monohydrate as an inactive ingredient, or excipient, in the extended-release tablet formulation. The presence of inactive ingredients like lactose monohydrate is typically noted for patients who need to consider its inclusion.

Q: Do studies suggest any specific time of day is better for taking Deslorin Plus?

A: Official dosing instructions focus on maintaining a consistent interval, instructing the product to be taken either once a day or twice a day (12 hours apart). Regulatory documents do not specify an optimal time of day (such as morning or night) but emphasize consistent timing and adherence to the prescribed frequency.

Q: Are there any known issues with Deslorin Plus for people with liver or kidney problems?

A: Yes, the drug is generally avoided or not recommended for patients with severe renal impairment (kidney problems) or hepatic impairment (liver problems). This precaution is in place because higher levels of the active ingredients may accumulate in the body, which could increase the chance of experiencing side effects.

How should Deslorin Plus be stored and disposed of?

Storage and Disposal of Deslorin Plus

The storage and disposal requirements for the Desloratadine/Pseudoephedrine combination tablet are strictly defined in regulatory documents to maintain product quality and safety.

Official Storage Conditions

Item Requirement
Temperature Store at Controlled Room Temperature, 25 C (77 F), with excursions allowed between 15 C and 30 C.
Protection Mandatory protection from light and moisture; do not store above 30 C.
Packaging Keep the tablets in their original outer carton and blister strip.
Child Safety Keep out of the sight and reach of children.

Disposal Mandates

All unused or expired Deslorin Plus must be disposed of in accordance with local requirements for pharmaceutical waste. Regulatory guidance generally advises against throwing the medicine away via wastewater or standard household trash. Disposal should typically utilize authorized drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deslorin Plus found in:

A-Z Index: